Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Jun 23, 2025
- Pharmaceuticals
- R&D
Eli Lilly’s Announcement Regarding Oral GLP-1 Orforglipron (Results of Phase III ACHIEVE-1 for Type 2 Diabetes Published in The New England Journal of Medicine)
TOKYO, June 23, 2025 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Eli Lilly and Company (hereafter “Eli Lilly”, NYSE: LLY) issued a news release on June 21, 2025 (local time), that the detailed results of the positive Phase 3 results from ACHIEVE-1 study, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone, were presented at the American Diabetes Association (ADA) 85th Scientific Sessions 2025 and simultaneously published in The New England Journal of Medicine.
Please refer to the Latest News via the following link, for details of Eli Lilly’s news release:
Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine
https://investor.lilly.com/
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp